MX2021000801A - Agonistas de il2. - Google Patents
Agonistas de il2.Info
- Publication number
- MX2021000801A MX2021000801A MX2021000801A MX2021000801A MX2021000801A MX 2021000801 A MX2021000801 A MX 2021000801A MX 2021000801 A MX2021000801 A MX 2021000801A MX 2021000801 A MX2021000801 A MX 2021000801A MX 2021000801 A MX2021000801 A MX 2021000801A
- Authority
- MX
- Mexico
- Prior art keywords
- human
- polynucleotides
- polypeptides
- host cells
- amino acid
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001136—Cytokines
- A61K39/00114—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
- A61K2039/55527—Interleukins
- A61K2039/55533—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Toxicology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
La invención se refiere a variantes de interleucina-2 (IL2). En una modalidad, las variantes de IL2 activan las células T efectoras sobre las células T reguladoras. En particular, la invención se refiere a un polipéptido que comprende una muteína de IL2 humana o una variante funcional de IL2 humana, en donde la IL2 humana o variante funcional de la misma se sustituye en al menos una posición que tiene un residuo de aminoácido ácido básico en la IL2 humana de tipo natural que hace contacto con la subunidad a del complejo del receptor ß? IL2 (IL2Raß?). Alternativamente, la muteína IL2 humana o de una variante funcional de la IL2 humana comprende al menos (i) una o más sustituciones de aminoácidos que reducen la afinidad para la subunidad alfa de ??_2?aß? y (ii) una o más sustituciones de aminoácidos que mejoran la afinidad para ??_2?ß?. La invención también se refiere a polinucleótidos que codician para los polipéptidos de la invención, células hospederas que comprenden los polinucleótidos, composiciones farmacéuticas que comprenden los polipéptidos, polinucleótidos o células hospederas, métodos terapéuticos o profilácticos de tratamiento que utilizan los polipéptidos, polinucleótidos, células hospederas o composiciones farmacéuticas y preparaciones médicas que comprenden los polipéptidos, polinucleótidos, células hospederas o composiciones farmacéuticas.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP2018070068 | 2018-07-24 | ||
| PCT/EP2019/069541 WO2020020783A1 (en) | 2018-07-24 | 2019-07-19 | Il2 agonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021000801A true MX2021000801A (es) | 2021-04-12 |
Family
ID=67439198
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021000801A MX2021000801A (es) | 2018-07-24 | 2019-07-19 | Agonistas de il2. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US12522640B2 (es) |
| EP (1) | EP3827014A1 (es) |
| JP (2) | JP7550745B2 (es) |
| KR (1) | KR20210038549A (es) |
| CN (1) | CN112771072B (es) |
| AU (1) | AU2019311233B2 (es) |
| BR (1) | BR112021000811A8 (es) |
| CA (1) | CA3106858A1 (es) |
| IL (1) | IL280290A (es) |
| MX (1) | MX2021000801A (es) |
| SG (1) | SG11202013044PA (es) |
| WO (1) | WO2020020783A1 (es) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110520436A (zh) | 2017-03-15 | 2019-11-29 | 潘迪恩治疗公司 | 靶向免疫耐受性 |
| EP3630163A4 (en) | 2017-05-24 | 2021-06-09 | Pandion Operations, Inc. | Targeted immunotolerance |
| BR112020002272A2 (pt) | 2017-08-03 | 2020-07-28 | Synthorx, Inc. | conjugados de citocina para o tratamento de doenças autoimunes |
| US10946068B2 (en) | 2017-12-06 | 2021-03-16 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| US10174091B1 (en) | 2017-12-06 | 2019-01-08 | Pandion Therapeutics, Inc. | IL-2 muteins |
| JP7512210B2 (ja) * | 2018-09-21 | 2024-07-08 | イノベント バイオロジックス （スウツォウ） カンパニー，リミテッド | 新規インターロイキン２およびその使用 |
| TW202031284A (zh) | 2018-11-08 | 2020-09-01 | 美商新索思股份有限公司 | 介白素10結合物及其用途 |
| US20200246467A1 (en) | 2019-02-06 | 2020-08-06 | Synthorx, Inc. | Il-2 conjugates and methods of use thereof |
| SG11202108857SA (en) * | 2019-03-18 | 2021-09-29 | Biontech Cell & Gene Therapies Gmbh | Lnterleukin-2 receptor (il2r) and interleukin-2 (il2) variants for specific activation of immune effector cells |
| MX2021014178A (es) | 2019-05-20 | 2022-01-04 | Pandion Operations Inc | Inmunotolerancia dirigida a la molecula de adhesion celular de adresina vascular de mucosas (madcam). |
| TW202115105A (zh) * | 2019-06-24 | 2021-04-16 | 德商拜恩迪克Ｒｎａ製藥有限公司 | Ｉｌ２激動劑 |
| EP4004025A1 (en) | 2019-07-26 | 2022-06-01 | Visterra, Inc. | Interleukin-2 agents and uses thereof |
| BR112022003046A8 (pt) | 2019-08-23 | 2024-02-06 | Synthorx Inc | Conjugado de il-15, seu método de preparo e seus usos, bem como composição farmacêutica e método in vitro de expansão de uma ou mais das populações de células t |
| EP4028060A1 (en) | 2019-09-10 | 2022-07-20 | Synthorx, Inc. | Il-2 conjugates and methods of use to treat autoimmune diseases |
| US12091440B2 (en) | 2019-12-20 | 2024-09-17 | Regeneron Pharmaceuticals, Inc. | IL2 and peptide-MHC complex fusion proteins and methods of use thereof |
| EP4107187A4 (en) | 2020-02-21 | 2024-07-03 | Pandion Operations, Inc. | TISSUE-TARGETED IMMUNOTOLERANCE WITH A CD39 EFFECTOR |
| WO2021178833A2 (en) * | 2020-03-05 | 2021-09-10 | The Board Of Trustees Of The Leland Stanford Junior University | Designed il-2 variants |
| CA3175728A1 (en) * | 2020-03-19 | 2021-09-23 | Innovent Biologics (Suzhou) Co., Ltd. | Interleukin-2 mutant and use thereof |
| CN118271419A (zh) | 2020-03-31 | 2024-07-02 | 韩美药品株式会社 | 新型免疫刺激il-2类似物 |
| EP4139341A1 (en) * | 2020-04-21 | 2023-03-01 | Regeneron Pharmaceuticals, Inc. | Il-2 variants with reduced binding to il-2 receptor alpha and uses thereof |
| EP4161956A1 (en) * | 2020-06-03 | 2023-04-12 | Ascendis Pharma Oncology Division A/S | Il-2 sequences and uses thereof |
| JP2023534793A (ja) * | 2020-07-09 | 2023-08-14 | ユーティレックス カンパニー リミテッド | Ｉｌ－２バリアント |
| US20240025956A1 (en) * | 2020-09-18 | 2024-01-25 | Miyagi Prefectural Hospital Organization | Il-2 mutant protein and medicine containing same |
| WO2022087458A1 (en) | 2020-10-23 | 2022-04-28 | Asher Biotherapeutics, Inc. | Fusions with cd8 antigen binding molecules for modulating immune cell function |
| TW202237171A (zh) | 2020-12-04 | 2022-10-01 | 美商威特拉公司 | 使用介白素-2藥劑之方法 |
| TW202317623A (zh) | 2021-06-14 | 2023-05-01 | 美商再生元醫藥公司 | 基於il2之治療劑及其使用方法 |
| EP4366779A1 (en) | 2021-07-09 | 2024-05-15 | Bright Peak Therapeutics AG | Modified tnf-antibodies and uses thereof |
| EP4460512A4 (en) * | 2022-01-07 | 2026-01-14 | Cure Genetics Co Ltd | NEW INTERLEUKIN-2 POLYPEPTIDES |
| IL314226A (en) * | 2022-01-11 | 2024-09-01 | Outpace Bio Inc | Designed cytokine compositions and methods of use |
| US20250215452A1 (en) | 2022-03-25 | 2025-07-03 | Universität Zürich | Adenoviral Mediated Targeting of Activated Immune Cells |
| TW202409069A (zh) * | 2022-07-01 | 2024-03-01 | 大陸商北京星奇原生物科技有限公司 | Ｉｌ－２多肽和使用方法 |
| WO2024083097A1 (zh) * | 2022-10-19 | 2024-04-25 | 北京志道生物科技有限公司 | 一种il-2突变体 |
| CN116041539B (zh) * | 2022-10-31 | 2023-07-21 | 山东博安生物技术股份有限公司 | Il-2突变体免疫缀合物 |
| KR20250096834A (ko) * | 2022-11-02 | 2025-06-27 | 베이징 창핑 래보러토리 | 융합 단백질 및 이의 용도 |
| CN121002050A (zh) * | 2023-02-21 | 2025-11-21 | 艾诺康医药公司 | 编码经修饰的白细胞介素2（il2）多肽的多核苷酸以及其制备和使用方法 |
| CN118620056A (zh) * | 2023-03-09 | 2024-09-10 | 北京天广实生物技术股份有限公司 | Il-2变体及其用途 |
| WO2024235281A1 (zh) * | 2023-05-17 | 2024-11-21 | 北京晶泰科技有限公司 | 白细胞介素-2变体及其应用 |
| CN119613562A (zh) * | 2023-09-14 | 2025-03-14 | 重庆精准生物技术有限公司 | 细胞因子融合蛋白及其应用 |
| WO2025212604A1 (en) * | 2024-04-01 | 2025-10-09 | Bio-Techne Corporation | Engineered il-2 polypeptides and conjugates, compositions, and uses thereof |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4281061A (en) * | 1979-07-27 | 1981-07-28 | Syva Company | Double antibody for enhanced sensitivity in immunoassay |
| FR2686899B1 (fr) | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant. |
| EP0873363B1 (en) * | 1995-06-14 | 2010-10-06 | The Regents of The University of California | High affinity human antibodies to tumor antigens |
| DZ2788A1 (fr) * | 1998-05-15 | 2003-12-01 | Bayer Ag | Agonistes et antagonistes selectifs à IL-2. |
| US20050287153A1 (en) | 2002-06-28 | 2005-12-29 | Genentech, Inc. | Serum albumin binding peptides for tumor targeting |
| US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
| US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
| US7176278B2 (en) | 2001-08-30 | 2007-02-13 | Biorexis Technology, Inc. | Modified transferrin fusion proteins |
| BR0214650A (pt) | 2001-12-04 | 2005-05-03 | Merck Patent Gmbh | Imunocitoquinas com seletividade modulada |
| US7615355B2 (en) * | 2002-04-22 | 2009-11-10 | Georgetown University | Peripheral-type benzodiazepine receptor expression level as an index of organ damage and regeneration |
| US7696320B2 (en) | 2004-08-24 | 2010-04-13 | Domantis Limited | Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor |
| WO2004022593A2 (en) * | 2002-09-09 | 2004-03-18 | Nautilus Biotech | Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules |
| ES2551682T3 (es) | 2002-11-08 | 2015-11-23 | Ablynx N.V. | Anticuerpos de dominio simple dirigidos contra factor de necrosis tumoral-alfa y usos para los mismos |
| US7569215B2 (en) | 2003-07-18 | 2009-08-04 | Massachusetts Institute Of Technology | Mutant interleukin-2 (IL-2) polypeptides |
| ES2567634T3 (es) | 2004-02-09 | 2016-04-25 | Human Genome Sciences, Inc. | Proteínas de fusión de albúmina |
| CN1930300A (zh) * | 2004-03-05 | 2007-03-14 | 希龙公司 | 预测患者治疗药物耐受性的体外试验系统 |
| JP2007527242A (ja) * | 2004-03-05 | 2007-09-27 | カイロン コーポレーション | 治療剤の患者耐容性を予測するためのインビトロ試験システム |
| US20070269422A1 (en) | 2006-05-17 | 2007-11-22 | Ablynx N.V. | Serum albumin binding proteins with long half-lives |
| CA2658654A1 (en) | 2006-07-24 | 2008-01-31 | Biorexis Pharmaceutical Corporation | Exendin fusion proteins |
| EP2069402A2 (en) | 2006-09-08 | 2009-06-17 | Ablynx N.V. | Serum albumin binding proteins with long half-lives |
| CA2583716A1 (en) * | 2007-04-18 | 2008-10-18 | Nautilus Biotech | Oral dosage formulations of protease resistant polypeptides |
| WO2009061853A2 (en) * | 2007-11-05 | 2009-05-14 | Massachusetts Institute Of Technology | Mutant interleukin-2 (il-2) polypeptides |
| BRPI0821924A2 (pt) | 2007-12-27 | 2015-07-07 | Novartis Ag | Moléculas de ligação baseadas em fibronectina melhoradas e seu uso |
| EA201001734A1 (ru) | 2008-05-02 | 2011-10-31 | Новартис Аг | Улучшенные связывающие молекулы на основе фибронектина и их применение |
| WO2011051478A1 (en) | 2009-10-30 | 2011-05-05 | Domain Therapeutics | Novel oxime derivatives and their use as allosteric modulators of metabotropic glutamate receptors |
| US10233228B2 (en) | 2010-04-09 | 2019-03-19 | Albumedix Ltd | Albumin derivatives and variants |
| CN105175532B (zh) | 2010-04-13 | 2023-01-17 | 百时美施贵宝公司 | 结合pcsk9的基于纤连蛋白的支架域蛋白质 |
| CN102101885B (zh) * | 2010-09-01 | 2013-06-05 | 南京发士达生物科技有限公司 | 低诱导抑制性t细胞的人白细胞介素ⅱ突变体及其用途 |
| WO2012088446A1 (en) | 2010-12-22 | 2012-06-28 | Board Of Trustees Of The Leland Stanford Junior University | Superagonists and antagonists of interleukin-2 |
| MX340671B (es) | 2011-02-10 | 2016-07-20 | Roche Glycart Ag | Polipeptidos interleuquina- 2 mutantes. |
| WO2012119093A1 (en) | 2011-03-03 | 2012-09-07 | Board Of Trustees Of The Leland Stanford Junior University | Superagonists and antagonists of interleukin-2 |
| US20140315817A1 (en) | 2011-11-18 | 2014-10-23 | Eleven Biotherapeutics, Inc. | Variant serum albumin with improved half-life and other properties |
| WO2013143555A1 (en) | 2012-03-26 | 2013-10-03 | Biontech Ag | Rna formulation for immunotherapy |
| WO2014145907A1 (en) * | 2013-03-15 | 2014-09-18 | Xencor, Inc. | Targeting t cells with heterodimeric proteins |
| CN106659757B (zh) | 2014-04-24 | 2022-01-28 | 利兰斯坦福初级大学董事会 | 白介素2的超级激动剂、部分激动剂和拮抗剂 |
| WO2017059902A1 (en) | 2015-10-07 | 2017-04-13 | Biontech Rna Pharmaceuticals Gmbh | 3' utr sequences for stabilization of rna |
| CU24483B1 (es) * | 2016-11-15 | 2020-04-02 | Ct Inmunologia Molecular | Método para incrementar los niveles de secreción de la interleucina-2 |
| AU2018287317B2 (en) * | 2017-06-19 | 2024-06-20 | Medicenna Therapeutics Inc. | Uses and methods for IL-2 superagonists, agonists, and fusions thereof |
-
2019
- 2019-07-19 AU AU2019311233A patent/AU2019311233B2/en active Active
- 2019-07-19 EP EP19744656.0A patent/EP3827014A1/en active Pending
- 2019-07-19 JP JP2021503723A patent/JP7550745B2/ja active Active
- 2019-07-19 KR KR1020217002155A patent/KR20210038549A/ko not_active Ceased
- 2019-07-19 CA CA3106858A patent/CA3106858A1/en active Pending
- 2019-07-19 CN CN201980049332.XA patent/CN112771072B/zh active Active
- 2019-07-19 MX MX2021000801A patent/MX2021000801A/es unknown
- 2019-07-19 US US17/262,097 patent/US12522640B2/en active Active
- 2019-07-19 SG SG11202013044PA patent/SG11202013044PA/en unknown
- 2019-07-19 BR BR112021000811A patent/BR112021000811A8/pt unknown
- 2019-07-19 WO PCT/EP2019/069541 patent/WO2020020783A1/en not_active Ceased
-
2021
- 2021-01-19 IL IL280290A patent/IL280290A/en unknown
-
2024
- 2024-04-19 JP JP2024068146A patent/JP2024099664A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP7550745B2 (ja) | 2024-09-13 |
| SG11202013044PA (en) | 2021-02-25 |
| EP3827014A1 (en) | 2021-06-02 |
| IL280290A (en) | 2021-03-01 |
| JP2021531013A (ja) | 2021-11-18 |
| BR112021000811A2 (pt) | 2021-04-13 |
| AU2019311233B2 (en) | 2025-01-09 |
| CN112771072B (zh) | 2025-01-07 |
| CN112771072A (zh) | 2021-05-07 |
| JP2024099664A (ja) | 2024-07-25 |
| KR20210038549A (ko) | 2021-04-07 |
| AU2019311233A1 (en) | 2021-01-21 |
| BR112021000811A8 (pt) | 2022-10-18 |
| US20210292386A1 (en) | 2021-09-23 |
| US12522640B2 (en) | 2026-01-13 |
| WO2020020783A1 (en) | 2020-01-30 |
| CA3106858A1 (en) | 2020-01-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021000801A (es) | Agonistas de il2. | |
| CO2021012380A2 (es) | Composición farmacéutica para inyección subcutánea que comprende una variante de hialuronidasa humana ph20 y un medicamento | |
| AR114445A1 (es) | Conjugados de il-15, y sus usos | |
| MX2020010075A (es) | Constructos de polipeptido de lisina-peptido anti-microbiano (amp), lisinas, polinucleotidos aislados que codifican para estas, y sus usos. | |
| AR067658A2 (es) | Un polipeptido inmunogenico, un polinucleotido que lo codifica , las composiciones farmaceuticas que contienen dichos polipeptidos y polinucleotido, los vectores de xpresion, vacunas, un metodo para la preparacion de dicho polipeptido y una celula huesped aislada que expresa dicho polipeptido | |
| CY1113117T1 (el) | Ηlα-α*3303-περιορισμενο wt1 πεπτιδιο και φαρμακευτικη συνθεση η οποια περιλαμβανει αυτο το ιδιο | |
| ATE466085T1 (de) | Protease-resistente modifizierte interferon alpha polypeptide | |
| CO2021017639A2 (es) | Agonistas de il2 | |
| BR112019018307A2 (pt) | Plataforma para identificação de peptídeos imunogênicos baseada em população | |
| ECSP12011803A (es) | Polipéptidos inmunomoduladores derivados de la il-2 y su uso terapéutico en cáncer y en infecciones crónicas | |
| BR112021013415A2 (pt) | Proteínas de fusão multifuncionais e usos das mesmas | |
| IL277790A (en) | Human neuregulin-1 recombinant chimeric protein preparations and methods of using them | |
| BR112018000660A2 (pt) | peptídeos anti-inflamatórios e seu uso | |
| MX2019006515A (es) | Composiciones que comprenden peptido wkdeagkplvk. | |
| EA202192555A1 (ru) | Комбинированная терапия для лечения рака | |
| BR112022007776A2 (pt) | Composições e métodos para minimizar a perda de proteína em baixas concentrações de proteína | |
| BR112022017032A2 (pt) | Composições compreendendo ltb e antígenos patogênicos, e uso das mesmas. | |
| CO2021000210A2 (es) | Apirasas solubilizadas, métodos y usos | |
| AR039629A1 (es) | Antagonistas de proteinas mcp | |
| NO20060675L (no) | Forbedrede, rekombinante, humane interferon-beta-lb-polypeptider | |
| ECSP22090761A (es) | Composiciones y métodos para suministrar agentes farmacéuticamente activos | |
| BR112022014567A2 (pt) | Métodos de purificação | |
| EA202092368A1 (ru) | Применение происходящих из pedf коротких пептидов при заживлении сухожилий | |
| AR128210A1 (es) | Variantes recombinantes del factor viii y sus usos | |
| AR114291A1 (es) | Conjugados de péptido tirosina tirosina cíclico con péptido de fusión del péptido similar al glucagón tipo 1 (glp-1) acoplado y usos de estos |